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Meeting Report
‘The Science of CAIM: What’s Next for Complementary,
Alternative and Integrative Medical Research?’
Elizabeth H. Logue
UCLA’s Office of the Vice Chancellor for Research and
Center for East West Medicine recently hosted a
symposium on the future of complementary, alternative
and integrative medical research featuring nationally
recognized speakers. The symposium took place on the
UCLA campus in late January and was targeted to the
Geffen School of Medicine’s Institutional Review Board
(IRB). Its purpose was to address the finding by the
National Center for Complementary and Alternative
Medicine (NCCAM) that IRB’s may be unfamiliar
and/or uncomfortable with unconventional medical
modalities thus apt to disapprove studies of those
modalities (1). The hope was to better this state of
affairs by familiarizing the audience with some of the
major controversies surrounding CAIM research and its
regulation.
As it turned out, NCCAM, itself came in for censure.
Dr Daniel Cherkin, Associate Director for Research and
Senior Investigator at Group Health in Seattle functioned
as moderator and began the program with a catalog of
ills from which the US health care system suffers, a
description of the role CAIM has played in responding to
those ills, a review of NCCAM’s mission and several
questions regarding how that mission has been and
should be carried out. A standing-room-only crowd then
heard Dr Donald Marcus, Professor of Medicine at
Baylor University and well-known CAIM critic and Dr
John Longhurst, Director of the Susan Samueli Center
for Integrative Medicine and Professor of Medicine at the
University of California at Irvine deliver their appraisals
of NCCAM. They decried the ‘too-low’ ratio of basic to
clinical research, what they view as the inordinate
influence on the Advisory Council and review panels of
CAIM practitioners, many of whom lack research
training and the investigation of ‘scientifically implausi-
ble’ therapies for which there is inadequate preliminary
data and which, in some cases may be dangerous.
NCCAM’s EDTA chelation trial was mentioned as
being especially ill-advised. While largely critical, both
speakers’ remarks included some praise. Dr Marcus made
reference to neuroscientific studies, work on the placebo
effect and negative trials of herbs as useful NCCAM
achievements. Dr Longhurst spoke of NCCAM’s unique
role in investigating modalities ignored by the rest of
NIH. Although he favors continued research on some
CAIM treatments, Dr Marcus opined that other NIH
Centers are equipped to take on such projects. He
repeated his call for an outside review of NCCAM, citing
his belief that political rather than scientific consider-
ations drive its agenda. He regards the situation as
untenable, particularly in an era of major cutbacks in
research funding. While not calling for an independent
review, Dr Longhurst spoke strongly in favor of reform,
a narrowing of the research agenda as well as an increase
in funding.
While Professors Longhurst and Marcus gave an
overview of the field of CAIM research, Dr Ary
Goldberger, Director of the Margret & H. A. Rey
Institute for Nonlinear Dynamics in Medicine at Boston’s
Beth Israel Deaconess Medical Center and Professor of
Medicine at Harvard Medical School discussed his work
on complex systems as one example of where such
research may be headed. In Dr Goldberger’s view,
conventionally designed studies frequently err in focusing
on only one molecular mechanism, ignoring communica-
tion among pathways and sometimes leading to unfore-
seen adverse outcomes. Dr Goldberger suggested that
conservatism in science extends to the underlying
approach to physiological systems, often wrongly
privileging homeostasis (‘constancy as the wisdom of
the body’) over complex adaptability, multi-scale
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properly cited.dynamics and emergent properties. In as much as they
are non-linear, non-stationary, non-additive and show
time irreversibility, however, complex systems may be
inaccessible to conventional analytic techniques, accord-
ing to the speaker. Dr Goldberger left the impression that
he believes both investigators and NIH Centers in general
ought to be more open to novel but rigorous research
designs and methodology.
On the subject of the criticisms leveled at NCCAM, the
speaker advocated ‘ruthless neutrality’ in all scientific
investigation but suggested that in its imperfection,
NCCAM in no way distinguishes itself from other NIH
Centers. He criticized the NIH system, generally, for a
tendency to reward ‘specific-aimsmanship’ in grant
writing over originality. He advocated the same non-
linearity of thought for the NIH that his work has shown
to be associated with good bodily health and adaptability
to stress. In noting that taxpayers ‘own’ NIH data,
Dr Goldberger suggested that NCCAM take a leadership
role in advocacy for open access data and open source
software, fostering scientific collaboration by allowing
validation of studies already completed.
NCCAM and CAIM leaders and investigators have
countered several of the arguments made by speakers
Longhurst and Marcus in the past (2–10) and UCLA
panelists echoed some of those responses, adding queries of
their own. Professor-in-Residence Mark Cohen expressed
the view that current research tools may be inadequate for
measuring the effects of some CAIM treatments. In
addition, he noted that taxpayers already support faith-
based initiatives and questioned whether conventional
science has a ‘special entitlement’ to public funds, given
that orientation. On the issue of the research agenda at
NCCAM, he made mention of the fact that in creating the
R21 grant, NIH acknowledged that existing funding
mechanisms didn’t sufficiently encourage creativity. With
regard to political considerations, he pointed out that these
have played a role in the creation of other NIH Centers,
including the National Institute of Biomedical Imaging and
BioEngineering (NIBIB). Noted UCLA cancer researcher
Dr Patricia Ganz seconded Cohen’s concern about
conservatism at NIH, recounting difficulties convincing
colleagues and reviewers of the need to study links between
the mind and body. She decried many investigators’
unwillingness to ‘think outside the heart’, a reference to
her observation that most rarely emerge from their
disciplinary ‘silos’. Dr Marcus agreed on the importance
of supporting some mind-body research, but indicated he
felt that funders have turned a corner and are now more
open to such work. Drs Ganz and Longhurst both spoke in
favor of the training of more persons capable of doing
rigorous science across disciplines.
Distinguished Professor Edwin Cooper (Editor in Chief,
Evidence Based Complementary and Alternative Medicine)
echoed others’ reluctance to single out NCCAM for
castigation. He, too, raised questions about what passes
for good research methodology, asking whether studying
ancient, whole systems of medicine using Western,
reductionistic techniques doesn’t strip them of essential
features. Associate Professor of Pediatrics, Jennie Tsao
agreed on the importance of investigating traditional
medicine as practiced remarking that for most users—
users in India and China, for example—such therapies are
not considered ‘alternative’. Dr Ganz added that some
non-western practices are associated with greater longevity
and may merit study as potential models for biomedicine as
it faces an epidemic of chronic disease. On the subject of
NCCAM’s achievements, Dr Tsao, suggested taking the
long view. She noted that psychological treatments such as
cognitive-behavioral therapy (CBT) now have an estab-
lished evidence base, thanks largely to sponsorship by the
National Institute of Mental Health (NIMH). However,
it took many years to separate empirically validated
approaches from those with little or no value. Thus, to
summarily dismiss a whole group of therapies as unsup-
ported would be premature, in her view. Dr Alison Moore,
an authority on geriatric alcoholism questioned speakers
on funding alternatives outside of NIH and opportunities
for training in CAIM research. Participants acknowledged
the difficulty of finding research dollars and Dr Longhurst
named several non-governmental sources he had used,
suggesting that young investigators look to such funding as
a bridge to support by NIH. After summarizing points
made by the speakers and panelists, Dr Cherkin concluded
that there is a need to broaden our view of what constitutes
good science and that systems-level investigations and a
focus onpatients’ concerns as they view them are important
means of achieving that end.
‘Science of CAIM’ was unusual in that it brought
together experts representing widely divergent opinions
on how complementary, alternative and integrative
modalities should be studied for a face-to-face discussion.
While consensus was not reached on most issues, the
symposium did succeed in offering those in the business
of evaluating CAIM proposals exposure to some of the
most pressing questions regarding its study and regula-
tion, thereby addressing concerns expressed in NCCAM’s
Strategic Plan. A pod cast of the symposium is available
at http://www.cewm.med.ucla.edu/podcasts/index.html
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